CorMedix Inc. (NASDAQ:CRMD) Q4 2022 Earnings Call Transcript

Joe Todisco: Thanks. I think we’ve communicated consistently we’re going to be prudent about how we utilize our cash and how we build out our infrastructure ahead of launch. We’ve started to build out leadership roles on the commercial side as well as probably let’s say deeper roles on the medical affair side where they can be out in the field now, having a lot of those disease state medical education type discussions with KOL. As we look at building out, right, the commercial field team, I think we’ll make that decision around timing as we see how the FDA meeting goes, get our resubmission and we’re not going to look to overburden the company in SG&A before we have a high level of confidence on final approval.

Dan Ferry: All right. Great. Joe, and our final question is, can you comment on the activity in recent months at conferences or medical meeting attendance and does the company have any upcoming presentations at scientific meetings or other activities worth noting?

Joe Todisco: Yes, look, I think our attendance have actually been pretty robust over the last few months both on the commercial and the medical affairs side at various meetings. I’d say, we’re probably averaging about two to three a month. We’ve had sponsorships and group presence at FSN, at ASH, at ASHP, we’ve got some upcoming in April and May, a lot of different acronyms RPA, NKF, FMDR so we’ll be out there and I think fairly aggressive and communicating, and getting the message about CRBSIs and critical unmet medical need kind of out into the marketplace.

Dan Ferry: Excellent. Thanks, Joe. Operator, this concludes the written question portion of the Q&A session.

Operator: Thank you. Ladies and gentlemen, this concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.